OBJECTIVES The purpose of this study was to evaluate the economic impact of the Absorb bioresorbable vascular scaffold compared with the Xience everolimus-eluting stent in patients undergoing percutaneous coronary intervention.
S
ince their introduction more than a decade ago, drug-eluting stents (DES) have been the dominant device used in percutaneous coronary revascularization. In recent years, first-generation DES have been supplanted by second-generation DES due to their improved efficacy and safety, both acutely and in the long term (1, 2) . Nonetheless, even current generation DES are limited by late adverse events, including stent thrombosis and restenosis (3) (4) (5) . It has been hypothesized that these suboptimal long-term outcomes may be related to effects caused by the permanent implantation of metal and polymers in the vessel wall, including inflammation, endothelial dysfunction, ongoing tissue growth within the stent frame, and neoatherosclerosis (6, 7) .
To reduce these late clinical consequences, fully bioresorbable stents that also elute antiproliferative drugs were developed. The design of the ABSORB III trial has been described previously (8) . Briefly, 2,008 patients undergoing PCI procedures, medication use, and rehospitalizations during the 1-year follow-up period were also collected. Major adverse cardiac events were adjudicated by an independent clinical events committee, who were blinded to treatment assignment.
DETERMINATION OF MEDICAL CARE COSTS
Medical care costs for the initial hospitalization as well as for the 1-year follow-up period were assessed using a combination of "bottom-up" and "top-down" methods as described previously (9) (10) (11) . All costs were assessed in 2015 U.S. dollars. Costs that were incurred in earlier years were converted to 2015 U.S. dollars using the medical care component of the Consumer Price Index. Discounting was not performed because costs were assessed only for 1-year of follow-up. (12) . Hospital charges were converted to costs using hospital-and cost center-specific cost-tocharge ratios (13, 14) . A linear regression model was Baron et al.
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Events associated with outpatient clinic visits, emergency room visits, procedures, and testing were mapped to Current Procedural Terminology codes, and costs were assigned based on the Medicare fee schedule. Outpatient antiplatelet agent use was assessed at each follow-up visit, and costs were assigned using the most current average wholesale prices from the Micromedex Red Book (19) .
Because there were no differences in the use of any other cardiac medications between the 2 groups, costs for these medications were excluded from our analysis. and were compared using t tests for in-hospital costs (which were normally distributed) and nonparametric bootstrapping for long-term costs (1,000 replicates).
RESULTS
PATIENT POPULATION. Baseline clinical and angiographic characteristics were well-matched between the 2 treatment groups ( Table 1 ). The mean age was 63 years, and the majority of patients were male. Of subjects, 30% were diabetic and 20% were current smokers. The most common indication for PCI was stable angina; however, approximately one-quarter of patients had unstable angina. The mean target lesion length was 15 mm with a mean diameter stenosis of 68% by quantitative coronary angiography.
INDEX PROCEDURAL RESOURCE USE AND COSTS.
Resource use and costs associated with the index procedure are summarized in Table 2 . In general, procedural resource use was similar for the 2 groups.
There were no differences in contrast volume, number of guiding catheters and guidewires used, or stent/scaffold implants between the 2 groups. DES ¼ drug-eluting stent(s); PCI ¼ percutaneous coronary intervention. Resource use and costs through the 1-year follow-up are shown in Based on bootstrap resampling, the probability that the total 1-year costs were lower with Absorb than Xience was 14.6% ( Figure 2) , and the probability that the difference in 1-year costs between Absorb and Xience was <$500 was 68.1%.
In our primary analysis, we assumed that the acquisition cost of the Absorb scaffold was $100
higher than the acquisition cost of the Xience stent.
To understand the influence of pricing on the economic impact of Absorb more fully, we performed a sensitivity analysis on the price difference between the Absorb scaffold and Xience stent ( Figure 3 ). As expected, the greater the cost difference between Absorb and Xience, the greater the 1-year cost difference between the 2 groups. If the acquisition cost of the Absorb scaffold was identical to that for the Xience stent, the 1-year cost difference would be $240.
DISCUSSION
This is the first prospective study to evaluate the economic outcomes associated with the use of a This lack of difference may reflect differences in practice early in the experience with this device as Baron et al.
Absorb scaffold was only recently approved in the United States, the cost of this device relative to other DES is both uncertain and likely to evolve over time.
Given these considerations, we believe that our approach of performing a sensitivity analysis with respect to alternative pricing was reasonable. WHAT IS NEW? We found that initial procedural costs were significantly higher with the Absorb scaffold than with the Xience stent (mainly due to greater balloon catheter use and the higher cost of the scaffold in the Absorb group); however, total 1-year costs did not differ between the 2 groups.
WHAT IS NEXT? Based on these 1-year data, there does not seem to be a major economic downside to the use of the Absorb scaffold at the present, although the true economic value of the device will be depend on whether late clinical outcomes (and associated effects on cost) emerges between the 2 groups.
